Provided by Tiger Trade Technology Pte. Ltd.

Alumis Inc.

6.97
+0.20002.95%
Post-market: 6.970.00000.00%19:50 EDT
Volume:2.85M
Turnover:19.67M
Market Cap:899.13M
PE:-1.83
High:7.02
Open:6.66
Low:6.61
Close:6.77
52wk High:31.35
52wk Low:4.28
Shares:129.00M
Float Shares:97.15M
Volume Ratio:1.14
T/O Rate:2.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8005
EPS(LYR):-2.8616
ROE:-93.65%
ROA:-45.34%
PB:1.99
PE(LYR):-2.44

Loading ...

Alumis Inc. : Leerink Partners Cuts Target Price to $26 from $34

THOMSON REUTERS
·
Sep 02

Small U.S. Stocks Decrease; Alumis Takes Biggest Hit

Dow Jones
·
Sep 02

Alumis price target lowered to $27 from $35 at Baird

TIPRANKS
·
Sep 02

Top Midday Decliners

MT Newswires Live
·
Sep 02

Alumis price target lowered to $25 from $51 at Wells Fargo

TIPRANKS
·
Sep 02

Alumis falls -58.9%

TIPRANKS
·
Sep 02

U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions

Reuters
·
Sep 01

Alumis Down over 54%, on Pace for Record Percent Decrease

Dow Jones
·
Sep 01

Alumis Set for Worst Day After Lupus Drug Misses Main Goal in Mid-Stage Trial

Reuters
·
Sep 01

Alumis Eyes Late-Stage Lupus Study Despite Trial Miss

Reuters
·
Sep 01

Alumis Reports Phase 2b Envudeucitinib Data in Lupus

TIPRANKS
·
Sep 01

Alumis' Lupus Drug Fails Mid-Stage Trial Goal

Reuters
·
Sep 01

Alumis Says Phase 2b LUMUS Trial of Envudeucitinib in Systemic Lupus Erythematosus Misses Primary Endpoint

Reuters
·
Sep 01

Alumis - Envudeucitinib Well Tolerated with no New Safety Signals in Lumus Trial

THOMSON REUTERS
·
Sep 01

Alumis - Lumus Phase 2B Trial of Envudeucitinib Did not Meet Primary and Secondary Endpoints

THOMSON REUTERS
·
Sep 01

Alumis - Robust Responses in Ifngs-High Subgroup Support Phase 3 Development of Envudeucitinib in Sle

THOMSON REUTERS
·
Sep 01

Alumis - on Track to Submit Nda for Envudeucitinib in Plaque Psoriasis in Q4 2026

THOMSON REUTERS
·
Sep 01

Alumis Announces Topline Results from Envudeucitinib Phase 2B Trial in Systemic Lupus Erythematosus (Sle)

THOMSON REUTERS
·
Sep 01

Alumis Inc. - Actively Evaluating Opportunities to Maximize Value of Our Oral Tyk2 Portfolio

THOMSON REUTERS
·
Sep 01

NASDAQ Trade Halt Halt News Pending at 07:25 Am

Reuters
·
Sep 01